Human BAFF (CD257) Recombinant

HomeSurface & Soluble Receptors

Human BAFF (CD257) Recombinant

$70.00 – $4,700.00

SKU: RKQ9Y275 Category: Surface & Soluble Receptors Tags: BAFF, BLYS, CD antigen CD257, Q9Y275, TALL-1, TALL1, TNFSF13B, TNFSF20, UNQ401/PRO738, ZTNF4

Description

Methods (5)


accession	Q9Y275

Source	Optimized DNA sequence encoding Human BAFF extracellular domain was expressed in Escherichia Coli
Molecular weight	Recombinant human Apolipoprotein E3, is a monomer protein consisting of amino acid residue subunits 134-285. The molecule has a calculated molecular mass of approximately 17kDa and migrates as an approximately 17kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity	>95%, as determined by SDS-PAGE and HPLC
Protein Sequence	AVQGPEETVT QDCLQLIADS ETPTIQKGSY TFVPWLLSFK RGSALEEKEN KILVKETGYF FIYGQVLYTD KTYAMGHLIQ RKKVHVFGDE LSLVTLFRCI QNMPETLPNN SCYSAGIAKL EEGDELQLAI PRENAQISLD GDVTFFGALK LL
Endotoxin	Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation	Recombinant Human BAFF was lyophilized from a 0.2 μm filtered solution in PBS, pH.5.
Reconstitution	A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers
Storage	The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage	This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor	O14836 TR13B_HUMAN
Interactor	O14836 TR13B_HUMAN
Biological Process	Immunity
Molecular function	Cytokine

Methods


RhoA is necessary for BAFF-mediated B cell survival but not proliferation. Splenic B220+ B cells from control and RhoA mice were cultured for 72 hours on 96-well plates (2×105 cells/well) with or without 2 µg/mL anti-IgM F(ab')2 antibody or indicated concentrations of BAFF (left).
Identification of IL21, CD40L, αIgM, BAFF and LPS regulated genes in transformed human germinal centre B cells using microarrays. BL2 cell were stimulated with αIgM F(ab)2 fragments (3 hrs) , IL21 (2 hrs) , CD40L (6 hrs) , LPS (6 hrs) and BAFF (9 hrs) .
(A) B cell activating factor (BAFF) mRNA expression in monocytes in patients with primary Sjögren's syndrome (pSS) (n=69) and healthy controls (HC) (n=44). BAFF mRNA expression was determined by real time quantitative-PCR.
(A) B cell activating factor (BAFF) mRNA expression in monocytes in patients with primary Sjögren's syndrome (pSS) (n=69) and healthy controls (HC) (n=44). BAFF mRNA expression was determined by real time quantitative-PCR.
Cell stimulation and total IgG production PBMCs recovered from the gradient interface were washed twice in PBS and adjusted to 10⁶cells/mL in RPMI 1640 supplemented with 10% FCS and 50 μg/mL gentamicin (GIBCO). Cells were cultured in the presence of 100 ng/mL rhIL-21 and/or 100 ng/mL rhBAFF for 12 days at 37°C with 5% CO_2. After 12 days, culture supernatants were collected and total IgG was measured using an in-house ELISA as described previously [